Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.
In the past week, Curasight signed a deal with Curium worth more than 70 MUSD, FDA issued a response letter to Ascendis Pharma, and many of the companies are preparing for earnings releases this week.
10 of the 20 listed, Danish biotech companies have published news the past week. 10 of the companies had a positive development in their share price for the week and 7 companies have had a positive share price performance year to date. Saniona has been the best performing stock this year.
Company news the past week
Ascendis Pharma
U.S. Food & Drug Administration Issues Complete Response Letter for TransCon™ PTH in Hypoparathyroidism (Link)
Ascendis Pharma to Participate in the BofA Securities 2023 Health Care Conference (Link)
No news the past week
Cessatech
No news the past week
No news the past week
Curasight and Curium announce global partnership for uTRACE[®] in prostate cancer (Link)
Evaxion Biotech
No news the past week
Expres2ion
ExpreS2ion Biotechnologies: ExpreS2ion – Annual report for 2022 published (Link)
Fluoguide
No news the past week
Genmab
Genmab will publish the interim report for the first quarter of 2023 on May 10.
Gubra
1. Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S’ shares (Link)
2. Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S’ shares (Link)
Initiator Pharma
Annual report and Remuneration report 2022 for Initiator Pharma A/S (Link)
Initiator Pharma Q1 2023 report (Link)
IO Biotech
No news the past week
Pila Pharma
No news the past week
Saniona
No news the past week
Scandion Oncology
No news the past week
SynAct Pharma
SynAct Pharma publishes Q1 2023 interim report (Link)
ViroGates
ViroGates announces its Interim Report for Q1, 2023: Quarterly revenue declined by 67% compared to Q1 due to a longer ramp-up period in Emergency Departments (Link)
Zealand Pharma
Zealand Pharma hosts conference call on May 11 at 2pm CET to present first quarter 2023 results
Y-mAbs Therapeutics
Y-mAbs to announce first quarter 2023 financial and operating results on May 8, 2023 (after the close of the U.S. financial markets)
2cureX
No news the past week
SELECTED CASES
SHARE PRICE DEVELOPMENTS
There were mixed developments among the Danish Biotech stocks last week. The average return was -3,7%. Ascendis Pharma AB rose the most with 35% after FDA issued a response letter for TransCon. Curasight also performed after they signed a deal with Curium for uTRACE in prostate cancer worth more than 70 MUSD. On the other hand, Scandion Oncology AB and Saniona AB became the worst performing Danish biotech stocks last week. Since the start of the year, most of the companies have delivered a negative return. However, the average return year-to-date is positive at 5,5% because a few companies as especially Zealand Pharma A/S, Fluoguide AB and Saniona AB have done really well.
Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment
Overview of share price developments the past week, year-to-date and last twelve months
